Literature DB >> 11069999

Characterization of transcripts expressed from human herpesvirus 6A strain GS immediate-early region B U16-U17 open reading frames.

L M Flebbe-Rehwaldt1, C Wood, B Chandran.   

Abstract

Several gene fragments of human herpesvirus 6 (HHV-6) have been shown to activate the human immunodeficiency virus (HIV) type 1 long terminal repeat (LTR). An open reading frame (ORF) designated B701 (Y. Geng, B. Chandran, S. F. Josephs, and C. Wood, J. Virol. 66:1564-1570, 1992), found within a 22-kb HHV-6A strain GS [HHV-6A(GS)] genomic fragment and a 3.8-kb SalI subfragment, was shown to activate the HIV LTR. B701, also known as HHV-6 U16, is located in the immediate-early B (IE-B) region of the genome. The sequence of the 3.8-kb genomic fragment of HHV-6A(GS) is nearly identical to the published sequence of HHV-6A strain U1102, with minor differences. The HHV-6A(GS) B701 ORF (U16) was used to screen an HHV-6A(GS) cDNA library, and two different but overlapping cDNAs were identified. These cDNAs represent differently spliced transcripts ending at different polyadenylation signals. The ORFs included in the cDNAs are positionally homologous to the human cytomegalovirus (HCMV) UL36 ORF. The ORF in one cDNA was generated by splicing together in frame ORFs U17 and U16, and the second cDNA included ORFs U16 and U15. A third differentially spliced cDNA (U16+), was identified by 5' rapid amplification of cDNA ends. The predicted protein was identical to the U16 portion of the U17/U16 spliced gene product but did not include the U17 portion. 5'-extension analyses of the mRNAs demonstrated that at least two potential transcription initiation sites were used to express the transcripts encoding U17 and U16 gene products. Single-stranded U16 and U17 gene-specific RNA probes hybridized with at least five RNA species from infected cells and demonstrated that the expression of these transcripts was differentially regulated. The U17/U16 spliced gene products were expressed at IE times after infection, but a multiply spliced gene product encoded by U16 was expressed as a late gene. The U17/U16 and the U16+ gene products transactivated the HIV LTR. Thus, while there are similarities to the HCMV UL36-UL38 gene family, some of the IE-B U17/U16 transcripts are unique to HHV-6.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11069999      PMCID: PMC113184          DOI: 10.1128/jvi.74.23.11040-11054.2000

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  38 in total

1.  Temporal mapping of transcripts in herpesvirus 6 variants.

Authors:  P Mirandola; P Menegazzi; S Merighi; T Ravaioli; E Cassai; D Di Luca
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

2.  RNA analysis and isolation of cDNAs derived from the human cytomegalovirus immediate-early region at 0.24 map units.

Authors:  D J Tenney; A M Colberg-Poley
Journal:  Intervirology       Date:  1990       Impact factor: 1.763

Review 3.  Analysis of the protein-coding content of the sequence of human cytomegalovirus strain AD169.

Authors:  M S Chee; A T Bankier; S Beck; R Bohni; C M Brown; R Cerny; T Horsnell; C A Hutchison; T Kouzarides; J A Martignetti
Journal:  Curr Top Microbiol Immunol       Date:  1990       Impact factor: 4.291

4.  Transactivation of human immunodeficiency virus promoter by human herpesvirus 6.

Authors:  R T Horvat; C Wood; N Balachandran
Journal:  J Virol       Date:  1989-02       Impact factor: 5.103

5.  Identification of proteins specific for human herpesvirus 6-infected human T cells.

Authors:  N Balachandran; R E Amelse; W W Zhou; C K Chang
Journal:  J Virol       Date:  1989-06       Impact factor: 5.103

6.  Molecular studies of HHV-6.

Authors:  S F Josephs; D V Ablashi; S Z Salahuddin; B Kramarsky; B R Franza; P Pellett; A Buchbinder; S Memon; F Wong-Staal; R C Gallo
Journal:  J Virol Methods       Date:  1988-09       Impact factor: 2.014

7.  Suppression of human immunodeficiency virus type 1 replication by human herpesvirus-6.

Authors:  D R Carrigan; K K Knox; M A Tapper
Journal:  J Infect Dis       Date:  1990-10       Impact factor: 5.226

8.  Transactivation of interleukin 2 and its receptor induces immune activation in human T-cell lymphotropic virus type I-associated myelopathy: pathogenic implications and a rationale for immunotherapy.

Authors:  C L Tendler; S J Greenberg; W A Blattner; A Manns; E Murphy; T Fleisher; B Hanchard; O Morgan; J D Burton; D L Nelson
Journal:  Proc Natl Acad Sci U S A       Date:  1990-07       Impact factor: 11.205

9.  Isolation of a new virus, HBLV, in patients with lymphoproliferative disorders.

Authors:  S Z Salahuddin; D V Ablashi; P D Markham; S F Josephs; S Sturzenegger; M Kaplan; G Halligan; P Biberfeld; F Wong-Staal; B Kramarsky
Journal:  Science       Date:  1986-10-31       Impact factor: 47.728

10.  Human herpes virus-6 increases HIV-1 expression in co-infected T cells via nuclear factors binding to the HIV-1 enhancer.

Authors:  B Ensoli; P Lusso; F Schachter; S F Josephs; J Rappaport; F Negro; R C Gallo; F Wong-Staal
Journal:  EMBO J       Date:  1989-10       Impact factor: 11.598

View more
  4 in total

Review 1.  Split genes and their expression in Kaposi's sarcoma-associated herpesvirus.

Authors:  Zhi-Ming Zheng
Journal:  Rev Med Virol       Date:  2003 May-Jun       Impact factor: 6.989

Review 2.  Update on human herpesvirus 6 biology, clinical features, and therapy.

Authors:  Leen De Bolle; Lieve Naesens; Erik De Clercq
Journal:  Clin Microbiol Rev       Date:  2005-01       Impact factor: 26.132

3.  Development of reverse transcriptase PCR assays for detection of active human herpesvirus 6 infection.

Authors:  G Van den Bosch; G Locatelli; L Geerts; G Fagà; M Ieven; H Goossens; D Bottiger; B Oberg; P Lusso; Z N Berneman
Journal:  J Clin Microbiol       Date:  2001-06       Impact factor: 5.948

4.  Efficacy of antiviral compounds in human herpesvirus-6-infected glial cells.

Authors:  Nahid Akhyani; Julie Fotheringham; Karen Yao; Farzin Rashti; Steven Jacobson
Journal:  J Neurovirol       Date:  2006-08       Impact factor: 2.643

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.